Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of selecting and treating patients with ovarian, primary liver, kidney, and thyroid cancers using its investigational therapy LP-184 (zirdafulven) based on a three-gene biomarker signature. The allowed claims cover the use of elevated expression of PTGR1, PTPN14, and ASPH to identify patients who may benefit from treatment with LP-184.
Lantern said its RADR(R) artificial intelligence platform helped identify the biomarker signature used in the patent, supporting the development of a precision medicine approach for LP-184. The company reported a 45% disease control rate among patients treated at or above the effective therapeutic dose in its Phase 1a trial and plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026 while continuing to expand its intellectual property portfolio.
For more details, view the full press release at https://ibn.fm/LRGUo.
Lantern Pharma Inc. is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR(R) platform to transform the development of cancer therapies. Its clinical pipeline includes LP-184, LP-284, and LP-300, which is being evaluated in the HARMONIC Phase 2 trial. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics. Additionally, withZeta.ai, Lantern's multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform.
Visit the company’s newsroom at https://ibn.fm/LTRN for the latest updates.
